FONR
FONAR Corporation14.35
-0.40-2.71%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
90.35MP/E (TTM)
12.93Basic EPS (TTM)
1.11Dividend Yield
0%Recent Filings
10-Q
8-K
FONAR FY2025 results mixed
FONAR reported fiscal 2025 results on September 12, 2025, with net revenues up 1% to $104.4 million, driven by a record 216,317 MRI scans—a 3.3% increase—via subsidiary HMCA, which now manages 44 scanners after adding two high-field units. Yet operating income fell 30% to $11.6 million amid 11% higher SG&A expenses, including a $2.3 million reserve for insurer risks. Net income dropped 24% to $10.7 million. Scan volumes grew unevenly, with Florida lagging due to tort reform.
8-K
Take-private proposal at $17.25/share
FONAR Corporation's Special Committee received a supplemental take-private proposal on July 18, 2025, from a group led by CEO Timothy Damadian to acquire all outstanding shares not already owned at $17.25 per share in cash, a 27% premium over the 90-day average closing price through June 30, 2025. The independent committee will review the non-binding offer with advisors to assess benefits for shareholders. No decisions yet. Uncertainty lingers on execution.
8-K
FONAR receives take-private proposal
FONAR Corporation's board received a non-binding proposal on July 7, 2025, from a group led by CEO Timothy Damadian—holding 5.01% of shares—to take the company private by acquiring all remaining outstanding stock at a premium of no less than 10% to the 90-day average closing price ending July 1, 2025. The board formed a special committee of independent directors to review the offer, prioritizing shareholder interests. No decisions yet. Deal completion remains uncertain without definitive agreements.
8-K
FONAR appoints expert director
FONAR Corporation appointed Robert M. Carrino, a Certified Public Accountant and partner at CFGI, LLC leading its SPAC practice, as an independent director on July 2, 2025, filling the vacancy from Claudette J.V. Chan's retirement on June 19, 2025. His extensive accounting expertise bolsters the board amid FONAR's transition to accelerated filer status and supports growth in its HMCA subsidiary, which now manages 44 MRI scanners across New York and Florida, up from nine in 2009. This addition sharpens financial oversight. Forward-looking statements note potential risks in SEC filings.
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BRKR
Bruker Corporation
44.96-0.71
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
FLGT
Fulgent Genetics, Inc.
27.16+0.24
ICLR
ICON plc
182.45-1.92
ILMN
Illumina, Inc.
131.56-3.36
NDRA
ENDRA Life Sciences Inc.
4.94-0.37
RDNT
RadNet, Inc.
71.22-1.35
TMO
Thermo Fisher Scientific Inc
570.16-5.75